Ocular Therapeutix
OCUL
271 hedge funds and large institutions have $1.77B invested in Ocular Therapeutix in 2026 Q1 according to their latest regulatory filings, with 79 funds opening new positions, 104 increasing their positions, 59 reducing their positions, and 51 closing their positions.
76% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 59
55% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 51
9% more funds holding
Funds holding: 249 → 271 (+22)
5.26% more ownership
Funds ownership: 89.91% → 95.17% (+5.3%)
4% more call options, than puts
Call options by funds: $22.1M | Put options by funds: $21.2M
24% less capital invested
Capital invested by funds: $2.33B → $1.77B (-$556M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$111M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$54.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$43.1M |
| 4 |
VA
VR Adviser
New York
|
+$28.9M |
| 5 |
CC
Commodore Capital
New York
|
+$24.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$56.1M |
| 2 |
Janus Henderson Group
London,
|
-$39.7M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$39M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$35.6M |
| 5 |
Millennium Management
New York
|
-$30.2M |
OCUL Hedge Fund Activity: Q1 2026 in Review
271 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2026, worth a combined $1.77B — down 24% from $2.33B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new OCUL positions and 51 closed out — a net gain of 28 holders — while 104 added to existing stakes and 59 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $111M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $56.1M sold.
- 271 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2026, up from 249 in Q4 2025.
- Funds reported $1.77B of Ocular Therapeutix stock for Q1 2026, down 24% quarter-over-quarter.
- 79 funds opened new Ocular Therapeutix positions in Q1 2026 and 51 closed out, a net change of +28 holders.
- The largest Ocular Therapeutix buyer in Q1 2026 was Deep Track Capital, an estimated $111M added.
- The largest Ocular Therapeutix seller in Q1 2026 was Adage Capital Partners, an estimated $56.1M sold.
Based on aggregated 13F filings for Q1 2026.